Doconazole is the antifungal agent. It is the first of the dioxolane series, which was later to produce ketoconazole, to appear as a potential drug. Antifungal activity of doconazole was compared with miconazole and amphotericin B activity against a number of pathogenic filamentous fungi. Doconazole was found to be more active than miconazole only against Coccidioides immitis and less active against A.fumigatus, B. dermatitidis, H.capsulatum and S.schenckii. Doconazole has been described as the drug of choice for oral treatment of murine coccidioidomycosis but was dropped because it produced glaucoma in dogs. Doconazole is used for the treatment of infections of the skin and mucous membranes caused by the Herpes simplex type 1 virus, including herpes of lips. Docosanol affects the fusion of the virus with the plasma membrane, which inhibits the penetration of the virus into the cell and its subsequent replication. Side effects are: dry skin, pruritus, rash, short-term redness, soreness, peeling, burning or tingling.